ClinicalTrials.gg
CompletedNCT02269241Updated Aug 6, 2019Results posted

Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles

A Phase 3 interventional study of LF111 (drospirenone) in Contraception, sponsored by Laboratories Leon Farma, S.A.. Completed at 37 sites in United States. Open to female participants aged 15 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-08-06.

Sponsored by Laboratories Leon Farma, S.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,552
Allocation
Not applicable
Ages
15 Years and older
Sex
Female
01

Study summary

To demonstrate the contraceptive efficacy of LF111 . To demonstrate the safety and tolerability of LF111 and assessment of pharmacokinetics of LF111.

Read the detailed description

This trial is a prospective, multicenter, open-label, non-controlled trial in female subjects, including adolescents between the ages of 15+(inclusive) who present to the clinic seeking contraception, who are postmenarcheal and premenopausal.

At screening, informed consent will be obtained and the screening procedures will be performed. After confirmation of the subject's eligibility, the subject will be provided with the investigational product and trained in the use of an electronic diary. Afterwards, the subjects will attend visit the clinical site on Day 20±2 of the 1st, 3rd, 6th and 9th cycles and on Day 29+2 of the 13th cycle. The last clinical site visit will occur 10-14 days after the 13th cycle visit.

The trial will include women who have never used hormonal contraceptives before consent (naïve users), women who have not used hormonal contraceptives in the past three months before consent or who have used hormonal contraceptives in the past but have a contraceptive-free time of less than three months before consent (previous users) as well as women directly switching from another hormonal method (switchers). Women who have used hormonal contraceptives in the past but have a contraceptive-free time of less than three months before consent are allowed to be included into the trial if they had at least one complete menstrual cycle before enrollment.

A population pharmacokinetic (PK) analysis planned in the whole subject population, will obtain sparse blood samples to determine plasma concentrations. In total, four blood samples will be collected: two samples each will be collected during the 1st cycle and during the 6th cycle of treatment.

Adverse events and safety information will be collected throughout the study.

02

Conditions studied

  • Contraception

Keywords

  • contraception
  • hormonal oral contraceptive agents
  • hormonal oral contraceptive
  • oral contraceptive
  • drospirenone
  • LF111
  • birth control
03

In context

Lead sponsor

This is the only study on the registry with Laboratories Leon Farma, S.A. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sexually active, postmenarcheal and premenopausal female subjects at risk of pregnancy including breastfeeding women with no upper age limit.
  2. Female subjects at risk of pregnancy, between the ages of 15 and 17 (inclusive) provided that

    • Applicable national, state and local laws allow subjects in this age group to consent/assent to receive services, and
    • All applicable laws and regulations regarding the /assent of the subjects to participate in clinical trials are observed.
  3. Regular cycles during the last six months before consent/assent when not using hormonal contraception.
  4. At least three complete menstrual cycles after delivery (only applicable for women who were pregnant within the last six months and for non-breastfeeding women). Breastfeeding women can be included six weeks after delivery irrespective of menstrual cycles post-delivery.
  5. At screening, maximum systolic blood pressure (median value of three values) ≤ 159 mm Hg and diastolic blood pressure (median value of three values) ≤ 99 mm Hg.
  6. Be able and willing to provide written informed consent or assent if the subject is adolescent, prior to undergoing any trial-related procedure.
  7. Willing to use trial contraception for thirteen 28-day cycles.
  8. Be willing to have intercourse each cycle of trial without the need to use back-up contraceptive.
  9. Be willing to state that, to her best knowledge, her male sexual partner(s):

    • Has not had a vasectomy or been previously diagnosed as infertile.
    • Has not been previously diagnosed or suspected of (HIV) unless he has subsequently had a negative HIV test.
    • Has not been known to have engaged in homosexual intercourse in the past five years unless he has had negative HIV test results since then.
    • Has not shared injection drug needles in the past unless he has had a negative HIV test at least six weeks since last use.
  10. Agree not to participate in any other clinical trials during the course of this trial.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant.
  2. Subject is known to or suspected of not being able to comply with the trial protocol, the use of the trial medication or the use of the trial diary.
  3. History of infertility.
  4. Abnormal finding on pelvic, breast or ultrasound examination that in the investigator's opinion contraindicates participation in the trial.
  5. Unexplained amenorrhea.
  6. Known polycystic ovary syndrome.
  7. Women ≥21 years of age with a Papanicolaou (pap) smear reading LGSIL or higher at screening (or six months prior to screening date). Human papilloma virus (HPV) testing in subjects with atypical squamous cells of undetermined significance (ASC-US) can be used as an adjunctive test.

    • Subjects with ASC-US can be included if they are negative for high-risk HPV strains.
    • Subjects \<21 years of age do not require a pap smear.
  8. Known or to ingredients or of the IMP ( Medicinal Product), including:

    1. Renal insufficiency
    2. Hepatic dysfunction
    3. Adrenal insufficiency
    4. Current or history of venous thrombophlebitis or thromboembolic disorders (venous thromboembolism, which includes deep vein thrombosis and pulmonary embolism)
    5. Current or history of cerebral-vascular or coronary-artery disease
    6. Valvular heart disease with thrombogenic complications
    7. Diabetes with vascular involvement
    8. Headaches with focal neurological symptoms
    9. Major surgery with prolonged immobilization
    10. Known or suspected carcinoma of the breast
    11. Known or suspected sex- sensitive
    12. Undiagnosed abnormal genital bleeding
    13. Cholestatic jaundice of pregnancy or jaundice with prior hormonal use
    14. Liver tumor (benign or malignant) or active liver disease.
  9. Uncontrolled thyroid disorder (i.e., on stable dose of thyroid replacement for less than two months).
  10. Uncontrolled concomitant diseases (i.e., not on a stable treatment dose for at least two months).
  11. Evidence or history of alcohol, medication or drug abuse (within the last 12 months prior to consent/assent).
  12. Known inherited or acquired predisposition to venous thromboembolism or arterial thromboembolism (e.g., factor V Leiden, Prothrombin mutation, Antiphospholipid antibodies) or bruising within the last 12 months prior to consent/assent.
  13. Known or suspected and/or hepatitis infection at screening.
  14. Received a dose of depot medroxyprogesterone acetate (DMPA or Depo-Provera®) during the 10 months prior to consent/assent, or received any combined injectable contraceptive (e.g., Cyclofem®) during the six months prior to consent/assent, or no spontaneous menses since last injection.
  15. Long-term treatment (longer than seven consecutive days within a month prior to V1b) of any medication that might interfere with the efficacy of hormonal contraceptives.

    Prohibited medication include:

    1. Anticonvulsants (e.g. phenytoin, carbamazepine, oxcarbazepine, topiramate, felbamate, primidone)
    2. Barbiturates
    3. Rifampin
    4. Bosentan
    5. Griseofulvin
    6. St. John's wort (hypericum perforatum)
  16. Administration of human chorionic gonadotropin (hCG) or intake of co-medication containing hCG within a month prior to V1b).
  17. Progestin-releasing intra-uterine device (IUD) or contraceptive implant received or in place within the last two months prior to consent/assent.
  18. Planned regular concomitant use of barrier contraceptive methods, spermicides, IUDs or other contraceptive measures (excepting occasional use for safety reasons, e.g., to reduce risk of infection).
  19. Evidence or history of clinically significant psychiatric illness or suicide risk.
  20. Participation in another trial of an investigational drug or device parallel to the current trial or less than 90 days before consent/assent, or previous participation in the current trial and dispensed trial medication.
  21. Subject is a member of the investigator's or Sponsor's staff or a relative or family member thereof.
  22. Any condition that, in the opinion of the investigator, may jeopardize protocol compliance or the scientific integrity of the trial.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,552 participants (actual)

Study arms

  • Experimental
    LF111 (drospirenone)

    single treatment arm receives LF111

    Drug: LF111 (drospirenone)

Interventions

  • One LF111 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.

    Also known as: CF111

06

What researchers measure

Primary outcomes

  1. Number of Pregnancies (Evaluable Cycles)

    Pearl index (PI) from Evaluable Cycles in non-breastfeeding women aged ≤ 35 years (at the time of trial enrollment). The PI calculation was based on the following formula: PI(evaluable cycles)= (∑ on-drug confirmed pregnancy ∈{exposure cycles})/(#{exposure cycles} ) X 1300

    Time frame: up to 13 months

Secondary outcomes

  1. Number of Pregnancies (All)

    Pearl Index based on overall cycles (overall PI) in women aged ≤ 35 years (at the time of trial enrollment) (confirmed pregnancies)

    Time frame: up to 13 months

  2. Number of Pregnancies (Method Failures)

    PI for method failures in women aged ≤ 35 years (at the time of trial enrollment) (confirmed pregnancies)

    Time frame: up to 13 months

  3. Pregnancy Ratio

    Pregnancy ratio in women aged ≤ 35 years (at the time of trial enrollment)

    Time frame: up to 13 months

  4. Overall PI, PI for Method Failures

    Overall PI, PI for method failures, PI (using evaluable cycles) and pregnancy ratio (life table analysis) in all women and in women up to 13 months (confirmed pregnancies)

    Time frame: up to 13 months

  5. Number of Participants With Adverse Events as a Measure of Safety

    Adverse events and changes in vital signs, clinical laboratory parameters

    Time frame: up to to 13 months

  6. Tolerability; Vaginal Bleeding Pattern

    Vaginal bleeding pattern

    Time frame: up to 13 months

Other outcomes

  1. Number of Pregnancies (by BMI and Weight)

    PI for evaluable cycles in women aged ≤ 35 years in total and by BMI and weight subgroups based on confirmed and on confirmed and suspected, non-confirmed pregnancies

    Time frame: up to 13 months

  2. Overall Pregnancies

    Overall PI based on confirmed and on confirmed and suspected, non-confirmed pregnancies in total and by BMI and weight subgroups

    Time frame: up to 13 months

07

Results

Posted Jul 23, 2019

Participant flow

Participant flow — Overall Study
MilestoneDrospirenone 4 mg
Started1552
Completed352
Not completed1200
Withdrew: Lost to follow-up269
Withdrew: Withdrawal by subject155
Withdrew: Protocol violation1
Withdrew: Physician decision7
Withdrew: Pregnancy15
Withdrew: Wish for pregnancy5
Withdrew: Development of an exclusion criteria16
Withdrew: Adverse event113
Withdrew: At the specific request of the sponsor20
Withdrew: Several reasons not classified53
Withdrew: Screening failures546

Outcome measures

PrimaryNumber of Pregnancies (Evaluable Cycles)

Pearl index (PI) from Evaluable Cycles in non-breastfeeding women aged ≤ 35 years (at the time of trial enrollment). The PI calculation was based on the following formula: PI(evaluable cycles)= (∑ on-drug confirmed pregnancy ∈{exposure cycles})/(#{exposure cycles} ) X 1300

Time frame:
up to 13 months
Reported as:
Number · Pearl Index
Number of Pregnancies (Evaluable Cycles)
Pearl IndexDrospirenone 4 mg
Number of Pregnancies (Evaluable Cycles)2.9 (1.5 to 5.1)
SecondaryNumber of Pregnancies (All)

Pearl Index based on overall cycles (overall PI) in women aged ≤ 35 years (at the time of trial enrollment) (confirmed pregnancies)

Time frame:
up to 13 months
Reported as:
Number · Pearl Index
Number of Pregnancies (All)
Pearl IndexLF111 (Drospirenone)
Number of Pregnancies (All)2.7 (1.4 to 4.7)
SecondaryNumber of Pregnancies (Method Failures)

PI for method failures in women aged ≤ 35 years (at the time of trial enrollment) (confirmed pregnancies)

Time frame:
up to 13 months
Reported as:
Number · Pearl Index
Number of Pregnancies (Method Failures)
Pearl IndexLF111 (Drospirenone)
Number of Pregnancies (Method Failures)3.4 (1.4 to 7.0)
SecondaryPregnancy Ratio

Pregnancy ratio in women aged ≤ 35 years (at the time of trial enrollment)

Time frame:
up to 13 months
Reported as:
Number · Cumulative Pregnancy Rate (%)
Pregnancy Ratio
Cumulative Pregnancy Rate (%)LF111 (Drospirenone)
Pregnancy Ratio2.46 (0.87 to 4.03)
SecondaryOverall PI, PI for Method Failures

Overall PI, PI for method failures, PI (using evaluable cycles) and pregnancy ratio (life table analysis) in all women and in women up to 13 months (confirmed pregnancies)

Time frame:
up to 13 months
Reported as:
Number · Pearl Index
Overall PI, PI for Method Failures
Pearl IndexLF111 (Drospirenone)
Overall PI, PI for Method Failures2.9 (1.2 to 6.1)
SecondaryNumber of Participants With Adverse Events as a Measure of Safety

Adverse events and changes in vital signs, clinical laboratory parameters

Time frame:
up to to 13 months
Reported as:
Number · Subjects
Number of Participants With Adverse Events as a Measure of Safety
SubjectsLF111 (Drospirenone)
Number of Participants With Adverse Events as a Measure of Safety667
SecondaryTolerability; Vaginal Bleeding Pattern

Vaginal bleeding pattern

Time frame:
up to 13 months
Reported as:
Number · Subjects with bleeding
Tolerability; Vaginal Bleeding Pattern
Subjects with bleedingLF111 (Drospirenone)
Tolerability; Vaginal Bleeding Pattern505
Other pre-specifiedNumber of Pregnancies (by BMI and Weight)

PI for evaluable cycles in women aged ≤ 35 years in total and by BMI and weight subgroups based on confirmed and on confirmed and suspected, non-confirmed pregnancies

Time frame:
up to 13 months
Reported as:
Number · Pearl Index
Number of Pregnancies (by BMI and Weight)
Pearl IndexLF111 (Drospirenone)
Pearl Index BMI<304.1 (2.0 to 7.3)
Pearl Index BMI>=302.9 (0.8 to 7.3)
Weight < Median5.1 (2.4 to 9.3)
Weight >= Median2.3 (0.8 to 5.5)
Other pre-specifiedOverall Pregnancies

Overall PI based on confirmed and on confirmed and suspected, non-confirmed pregnancies in total and by BMI and weight subgroups

Time frame:
up to 13 months
Reported as:
Number · Pearl Index
Overall Pregnancies
Pearl IndexLF111 (Drospirenone)
Pearl Index BMI<303.3 (1.7 to 6.0)
Pearl Index BMI>=302.3 (0.6 to 5.8)
Weight < Median4.2 (2.0 to 7.7)
Weight >= Median1.9 (0.6 to 4.4)

Adverse events

Collected over 3 years. Non-serious events are listed at a 0.5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Drospirenone 4mg0/1,006 (0%)17/1,006 (1.7%)341/1,006 (33.9%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventDrospirenone 4mg
HYPERKALAEMIAMetabolism and nutrition disorders5/1006
CHOLECYSTITIS ACUTEHepatobiliary disorders1/1006
DRUG ABUSEPsychiatric disorders1/1006
INTRACRANIAL ANEURYSMNervous system disorders1/1006
APPENDICITISInfections and infestations1/1006
ECTOPIC PREGNANCYPregnancy, puerperium and perinatal conditions1/1006
ABDOMINAL PAIN UPPERGastrointestinal disorders1/1006
OVERDOSEInjury, poisoning and procedural complications1/1006
BILIARY COLICHepatobiliary disorders1/1006
CELLULITISInfections and infestations1/1006
Most frequent other events
Showing 10 of 29
Most frequent other events
EventDrospirenone 4mg
MetrorrhagiaReproductive system and breast disorders52/1006
HeadacheNervous system disorders47/1006
DysmenorrhoeaReproductive system and breast disorders44/1006
Breast painReproductive system and breast disorders43/1006
NauseaGastrointestinal disorders40/1006
Breast tendernessReproductive system and breast disorders30/1006
AcneSkin and subcutaneous tissue disorders30/1006
Weight increasedInvestigations23/1006
MenorrhagiaReproductive system and breast disorders17/1006
Vaginal haemorrhageReproductive system and breast disorders12/1006

Baseline characteristics

1552 patients enrolled, 546 patients screening failures, 1006 patients analyzed, 352 patients completed

Age, Customized
Age, Customized(participants)LF111 (Drospirenone 4mg)
<=35 years928
>35 years78
Sex: Female, Male
Sex: Female, Male(Participants)LF111 (Drospirenone 4mg)
Female1006
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LF111 (Drospirenone 4mg)
Hispanic or Latino229
Not Hispanic or Latino777
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LF111 (Drospirenone 4mg)
American Indian or Alaska Native13
Asian20
Native Hawaiian or Other Pacific Islander5
Black or African American358
White571
More than one race0
Unknown or Not Reported39
08

Study locations

37 sites
  • Alabama Clinical Therapeutics
    Birmingham, Alabama 35235, United States
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • WCCT Global
    Costa Mesa, California 92626, United States
  • Women's Health Care Research Corp.
    San Diego, California 92123, United States
  • Downtown Women's Health Care
    Denver, Colorado 80209, United States
  • Horizons Clinical Research Center, LLC
    Denver, Colorado 80220, United States
  • Stamford Therapeutics Consortium
    Stamford, Connecticut 06095, United States
  • Altus Research
    Lake Worth, Florida 33461, United States
  • Miami Research Associates
    Miami, Florida 33143, United States
  • Segal Institute for Clinical Research
    North Miami, Florida 33161, United States
  • Meridien Research - St. Petersburg
    Saint Petersburg, Florida 33709, United States
  • Meridien Research - Tampa
    Tampa, Florida 33606, United States
  • Comprehensive Clinical Trials, LLC
    West Palm Beach, Florida 33409, United States
  • Fellows Research Alliance, Inc.
    Savannah, Georgia 31406, United States
  • Rosemark WomenCare Specialists
    Idaho Falls, Idaho 83404, United States
  • Bluegrass Clinical Research, Inc
    Louisville, Kentucky 40291, United States
  • Johns Hopkins School of Medicine
    Baltimore, Maryland 21224, United States
  • Beyer Research
    Kalamazoo, Michigan 49009, United States
  • Lawrence OBGYN Clinical Research, LLC
    Lawrenceville, New Jersey 08648, United States
  • The Center for Women's Health & Wellness, LLC
    Plainsboro, New Jersey 08536, United States
  • Southwest Clinical Research
    Albuquerque, New Mexico 87109, United States
  • NYU School of Medicine
    New York, New York 10016, United States
  • Eastern Carolina Women's Center
    New Bern, North Carolina 28562, United States
  • Wake Research Associates
    Raleigh, North Carolina 27612, United States
  • Hawthorne Medical Research, Inc.
    Winston-Salem, North Carolina 27103, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
  • Columbus Obstetricians-Gynecology, Inc./Radiant Research, Inc.
    Columbus, Ohio 43213, United States
  • University of Pennsylvania School of Medicine
    Philadelphia, Pennsylvania 19104, United States
  • Clinical Research Of Philadelphia
    Philadelphia, Pennsylvania 19114, United States
  • Fellows Research Alliance, Inc.
    Bluffton, South Carolina 29910, United States
  • Advanced Research Associates
    Corpus Christi, Texas 78414, United States
  • Practice Research Organization
    Dallas, Texas 75230, United States
  • TMC Life Research, Inc.
    Houston, Texas 77054, United States
  • Physicians' Research Options
    Draper, Utah 84020, United States
  • Physicians' Research Options
    Pleasant Grove, Utah 84062, United States
  • Eastern Virginia Medical School
    Norfolk, Virginia 23507, United States
  • Seattle Women's Health, Research, Gynecology
    Seattle, Washington 98105, United States
09

References and documents

Publications

  • Palacios S, Colli E, Regidor PA. Efficacy and cardiovascular safety of the new estrogen-free contraceptive pill containing 4 mg drospirenone alone in a 24/4 regime. BMC Womens Health. 2020 Oct 2;20(1):218. doi: 10.1186/s12905-020-01080-9. PubMed 33008401 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2014 to primary completion in Oct 2017, 35 months.

Results were first posted in Jul 2019, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2014
First posted
Oct 21, 2014
StartActual
Oct 9, 2014
Primary completionActual
Oct 4, 2017
CompletionActual
Oct 4, 2017
Results first posted
Jul 23, 2019
Last update
Aug 6, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02269241
Lead sponsor
Laboratories Leon Farma, S.A.
Collaborators
Chemo France
Responsible party
Sponsor
First posted
Oct 21, 2014
Start date
Oct 9, 2014
Primary completion
Oct 4, 2017
Completion
Oct 4, 2017
Results posted
Jul 23, 2019
Last update
Aug 6, 2019

Study contacts

Enrico Colli, MD
study director · Exeltis

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Drospirenone

Start the discussion